Press Releases

Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON’s PlaCCine modality and its applicability to multiple pathogens LAWRENCEVILLE, N.J. , Nov. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company focused on harnessing the power of

Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Conference Call Begins Today at 10:00 a.m. ET LAWRENCEVILLE, N.J. , Nov. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc.

LAWRENCEVILLE, N.J. , Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m.

Highlights advantages of IMUNON’s PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J. , Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company focused on harnessing the power of the immune system against cancer and infectious

“ A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics” presented by the Foreign Policy Association LAWRENCEVILLE, N.J. , Oct. 19, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company focused on harnessing the power of the immune system against

The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J. , Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and

Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas ™ and Indiplas ™ modalities in immuno-oncology. LAWRENCEVILLE, N.J. , Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing

Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS and OS trend compared with control arm Continued follow-up is indicated to confirm initial observations LAWRENCEVILLE, N.J. , Sept.

Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J. , Sept. 26, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated

Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J. , Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq:   IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and